Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aramchol - Galmed Pharmaceuticals

Drug Profile

Aramchol - Galmed Pharmaceuticals

Alternative Names: Arachidyl amido cholanoic acid; Arachidyl amido cholanoic acid - Galmed Pharmaceuticals; Aramchol

Latest Information Update: 30 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Galmed Medical Research
  • Developer Galmed Medical Research; Galmed Pharmaceuticals; University of California, San Diego
  • Class Antifibrotics; Bile acids and salts; Cholic acids; Drug conjugates; Eicosanoic acids; Eicosanoids; Fatty acids; Hepatoprotectants; Small molecules
  • Mechanism of Action Stearoyl-CoA desaturase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Lipodystrophy

Highest Development Phases

  • Phase III Fibrosis; Non-alcoholic steatohepatitis
  • Phase II Cholelithiasis; Lipodystrophy; Non-alcoholic fatty liver disease

Most Recent Events

  • 26 Sep 2019 Phase-III clinical trials in Fibrosis in USA (PO) (NCT04104321)
  • 26 Sep 2019 Phase-III clinical trials in Non-alcoholic steatohepatitis in USA (PO) (NCT04104321)
  • 07 May 2019 Galmed Pharmaceuticals plans the pivotal phase III/IV ARMOR trial for Non-alcoholic steatohepatitis in the U.S., Europe, Latin America and Asia the third quarter of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top